Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01761266 · ClinicalTrials.gov registry record · Phase 3
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
A Phase 3 study, sponsored by Eisai Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 954
- Enrollment target
NCT01761266: Completed Phase 3 study, sponsored by Eisai Limited.
NCT01761266 is a Phase 3 study that has completed, run by Eisai Limited. The registered enrollment target is 954 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01761266, a Phase 3 study, has completed, sponsored by Eisai Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 954 participants
- Enrollment target
Study Summary
E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable Hepatocellular Carcinoma (HCC).
Interventions
- DRUG Lenvatinib
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 954 participants |
| Start Date | 2013-03-01 |
| Est. Completion | 2021-03-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01761266
The ClinicalTrials.gov registry entry for NCT01761266 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 954 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenvatinib is the first listed.
NCT01761266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01761266 about?
NCT01761266 is a clinical study titled "A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma". E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable Hepatocellular Carcinoma (HCC).
What is the current status of trial NCT01761266?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 954 participants. The study started on 2013-03-01. Estimated completion is 2021-03-10.
What interventions are being tested in trial NCT01761266?
The interventions under investigation include: Lenvatinib (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT01761266?
This trial is sponsored by Eisai Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.